Overview of the 2014 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting about vorapaxar.
Citation: Circulation. 130(15):1287-94, 2014 Oct 7.PMID: 25287768Institution: MedStar Heart & Vascular InstituteForm of publication: Journal ArticleMedline article type(s): CongressesSubject headings: *Acute Coronary Syndrome/pc [Prevention & Control] | *Drug Approval | *Lactones/tu [Therapeutic Use] | *Plaque, Atherosclerotic/pc [Prevention & Control] | *Platelet Aggregation Inhibitors/tu [Therapeutic Use] | *Pyridines/tu [Therapeutic Use] | Clinical Trials Data Monitoring Committees | Hemorrhage/ep [Epidemiology] | Humans | Lactones/ae [Adverse Effects] | Platelet Aggregation Inhibitors/ae [Adverse Effects] | Pyridines/ae [Adverse Effects] | Receptor, PAR-1/ai [Antagonists & Inhibitors] | Risk Assessment | United StatesYear: 2014Local holdings: Available online from MWHC library: 1950 - present, Available in print through MWHC library: 1999 - 2006ISSN:- 0009-7322
Item type | Current library | Collection | Call number | Status | Date due | Barcode |
---|---|---|---|---|---|---|
Journal Article | MedStar Authors Catalog | Article | 25287768 | Available | 25287768 |
Available online from MWHC library: 1950 - present, Available in print through MWHC library: 1999 - 2006
English